Capricor Therapeutics Inc
CAPR
Get informed when a big investor buys or sells
+ FollowMarket Cap$450.31M
Close$
$5.81
20.1% downside
Current Fair Value
20.1% downsideOvervalued by 20.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $450.31 Million |
|---|---|
| Enterprise Value | $82.56 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.26 |
| Beta | 0.53 |
| Outstanding Shares | 57,926,347 |
Return
| Return on Equity | -16.58% |
|---|---|
| Return on Assets | -11.07% |
| Return on Invested Capital | -12.82% |
Valuation & Multiples
| P/E Ratio | -3.2 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.92 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 1.25 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$2.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$41.71 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 47.26% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 68.17% |
|---|---|
| Total Invested | $27,018▼ 100.00% |
| Investors Holding | 4▼ 192.00% |
ESG Score
No data
About Capricor Therapeutics Inc
CEO: Linda Marban